Immunological and Autoimmune Disorders

Novartis eyes $8B Amneal buy Novartis is weighing a deal for the generics maker Amneal Pharmaceuticals to expand its already-hefty Sandoz unit, at a time when two of its biggest rivals in the field are integrating big buyouts of their own. The Amneal buy could be worth up to $8 billion. Joerg Reinhardt, chairman of the Swiss drug maker, made the broadest suggestion yet that Alcon’s days under Novartis’ umbrella are numbered. The ophthalmology unit has been struggling in recent quarters, and Reinhardt suggested that Alcon needs to recover soon, or face life under new ownership. Pfizer considers cashing in on its consumer health business Rumour mills are going abuzz wit...